Thiogenesis Therapeutics Advances in Mitochondrial Disease Trials

Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.

Thiogenesis Therapeutics Corp. has announced progress in its clinical programs for mitochondrial diseases, highlighting its upcoming Phase 2 trial for MELAS in Europe and a planned Phase 2a trial for Leigh Syndrome in partnership with a leading US children’s hospital. These developments underscore the company’s commitment to addressing rare mitochondrial disorders using its novel thiol compounds.

For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.